Pritelivir Demonstrated Superior Efficacy Compared to Investigator’s Choice Treatment for Refractory Herpes Simplex Virus Infections In Immunocompromised Patients: PRIOH-1, Phase 3 Safety and Efficacy

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Genovefa A. Papanicolaou, Robin K. Avery, Kimberly Workowski, Karl S Peggs, Yeon Joo Lee, Jean-Michel Molina, Anum Abbas, Alma Minerva Pérez-Ríos, Jana Dickter, Sanjeet Singh Dadwal, Stuart H. Cohen, Nicolas Issa
+9 more Palash Samanta, Alexander Birkmann, Cynthia Wat, Dilruwan Chaminda Herath, Alessandra Marini, Bernadette Surujbally, MelanieRPh SumnerMSc, Anna Wald, Roy F. Chemaly
DOI: 10.1016/j.jtct.2026.02.038
Cited by: 3

Fields of Study & Subjects

Herpesvirus Infections and Treatments Cytomegalovirus and herpesvirus research Virus-based gene therapy research

Publication details

Journal / source
Transplantation and Cellular Therapy
Publisher
Elsevier BV
Volume
32
Issue
3
Pages
S18–S19
Publication date
1 March 2026
Language
EN